Sustained CD4 and CD8 lymphopenia after rituximab maintenance therapy following bendamustine and rituximab combination therapy for lymphoma

Leuk Lymphoma. 2015;56(11):3216-8. doi: 10.3109/10428194.2015.1026818. Epub 2015 May 12.

Authors

Tsutsumi Yutaka¹, Shinichi Ito¹, Hiroyuki Ohigashi¹, Miyashita Naohiro¹, Joji Shimono¹, Shiratori Souichi¹, Takanori Teshima²

Affiliations

¹ a Department of Hematology , Hakodate Municipal Hospital , Hakodate , Japan.
² b Department of Hematology , Hokkaido University Graduate School of Medicine , Sapporo , Japan.

PMID: 25760636
DOI: 10.3109/10428194.2015.1026818

No abstract available

Publication types

Letter

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Bendamustine Hydrochloride / administration & dosage
CD4-Positive T-Lymphocytes*
CD8-Positive T-Lymphocytes*
Humans
Lymphocyte Count
Lymphoma / complications*
Lymphoma / drug therapy*
Lymphopenia / blood
Lymphopenia / diagnosis
Lymphopenia / etiology*
Maintenance Chemotherapy
Rituximab / administration & dosage
Rituximab / adverse effects
Rituximab / therapeutic use*

Substances

Rituximab
Bendamustine Hydrochloride